Physostigmine, Eserine

Physostigmine, Eserine

Physostigmine; Eserine; Antilirium; Physostol; Esromiotin

Bi miotic, Bi-miltic

(3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate

Absorption: SC tissues, GI tract, mucous membranes

Metabolism: hydrolyzed by cholinesterase’s

Excretion: Through renal

Physostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor which effectively increases the concentration of acetylcholine at the sites of cholinergic transmission. Physostigmine inhibits acetylcholinesterase, the enzyme responsible for the breakdown of used acetylcholine. By interfering with the metabolism of acetylcholine, physostigmine indirectly stimulates both nicotinic and muscarinic receptors due to the consequential increase in available acetylcholine at the synapse.

• Intravenous injection-1 mg/mL
• Liquid dosage form-Intramuscular; Intravenous-1 mg

Glaucoma

Nausea, vomiting, diarrhea, muscle weakness, sweating, shortness of breath, blurred vision, abdominal/stomach pain or cramp.

Concurrent use of belladonna alkaloids (ophthalmic)/ may antagonize the miotic and antiglaucoma actions of physostigmine.

Contraindicated in pregnancy, asthmatic patients and gangrene.

Store in a tight container, do not freeze. Preferably store at a temperature between 15 and 30 deg C.

Molecular weight

275.35

Molecular formula

C15H21N3O2

CAS number

57-47-6

Precautions

• If excessive sweating or nausea occurs, the dosage should be reduced.
• If excessive symptoms of salivation, emesis, urination and defecation occur, the use of Physostigmine Salicylate (physostigmine salicylate (injection)) Injection should be terminated.